Neogen Corporation 8-K Filing Summary

Neogen Corporation reported its fiscal 2026 third quarter results on April 9, 2026. The company experienced a total revenue of $211.2 million, a decrease of 4.4% compared to the previous year. The Food Safety segment showed growth of 2.6%, reaching $156.7 million, with core growth at 4.0%. However, the Animal Safety segment revenue decreased by 20.1% to $54.5 million, with core growth at (8.7%), primarily due to third-party supplier challenges. The company reported a net loss of $17.0 million for the quarter. Neogen announced the divestiture of its Genomics business unit, expected to close in 2Q27, with net proceeds supporting debt reduction goals. The company is raising its fiscal year 2026 revenue outlook to $857-$860 million while maintaining its Adjusted EBITDA guidance of approximately $175 million. Operational highlights include progress on the Petrifilm manufacturing transition and a review of the go-to-market strategy.